JPRN-jRCT2031220415招募中2 期
A Phase II, placebo-controlled, randomized, double-blind, parallel-group, single-center study to evaluate efficacy and safety of M528101 in patients with postherpetic neuralgia
Tomoyuki Nishiura0 个研究点目标入组 18 人开始时间: 2022年10月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Postherpetic neuralgia patients aged 18 years and older
排除标准
- •(1)Patients with herpes zoster skin symptoms (edematous erythema, blisters, erosions, crusts) or other epidermal abrasions (erosions, ulcers, fissures) at the drug administration site (postherpetic neuralgia expression site)
- •(2)Patients with symptoms or treatment history (including neurodestructive drugs and radiofrequency thermocoagulation) that the investigator (subinvestigator) judges may affect the pain NRS evaluation of postherpetic neuralgia
- •(3)Patients who have or are currently undergoing drug treatment with opioids for postherpetic neuralgia
研究者
相似试验
招募中
2 期
A Phase II study of M605110 for axillary osmidrosisaxillary osmidrosisJPRN-jRCT2031220072Tomoyuki Nishiura105
招募中
2 期
A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptomsEarly progressive diffuse cutaneous systemic sclerosisJPRN-jRCT2041220079Ogawa Shintaro200
招募中
2 期
A Trial to Compare BI drug with Placebo for Patients With SclerodermaCTRI/2023/07/054769Boehringer Ingelheim
招募中
1 期
A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptomssystemic sclerosisCTIS2022-500332-11-00Boehringer Ingelheim International GmbH200
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsChronic HIV-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002724-83-BEErasmus MC70